Pancreatic Cancer Research

ResearcherUniversity of BernActive in the last 2 years

Mirjam Schenk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1637-0730; OpenAlex author ID A5001238403. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
9
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 4

  1. Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00535-026-02347-y↗
  2. TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.omton.2025.201034↗
  3. Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. First author DOI 10.3390/cancers14040985↗
  4. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2021.643529↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Robatel · 3 shared papers, 2022–2026 · strength 0.82
  2. Martin Wartenberg · 2 shared papers, 2025–2026 · strength 0.49
  3. Max Nobis · 1 shared paper, 2026 · strength 0.25
  4. Ulf Kessler · 1 shared paper, 2026 · strength 0.25
  5. Lina Gross · 1 shared paper, 2025 · strength 0.24
  6. Hassan Sadozai · 1 shared paper, 2021 · strength 0.15
  7. Beat Gloor · 1 shared paper, 2021 · strength 0.15
  8. Animesh Acharjee · 1 shared paper, 2021 · strength 0.15
  9. Eva Karamitopoulou · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.